Fluorescent PLGA-CY5 from PolySciTech used in development of anti-inflammatory drug delivery for arthritis treatment.

 

Rheumatoid arthritis, is an autoimmune and inflammatory disease where the immune system attacks healthy cells in the joints. One way to reduce the progress of arthritis is to reduce the inflammatory response at the location of the joint tissue to stop the immune attack. Researchers at University of California San Diego and University of Gothenburg (Sweden) used PLGA (cat# AP041) and PLGA-CY5 (cat# AV034) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create fluorescently stained PLGA microparticles to deliver anti-inflammatory trans retinoic acid to joint tissue. This research holds promise to improve therapies against arthritis in the future. Read more: McBride, David A., Matthew D. Kerr, Wade T. Johnson, Anders Nguyen, Martina Zoccheddu, Mina Yao, Edward B. Prideaux et al. "Immunomodulatory Microparticles Epigenetically Modulate T Cells and Systemically Ameliorate Autoimmune Arthritis." Advanced Science (2023): 2202720. https://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202202720

“Abstract: Disease modifying antirheumatic drugs (DMARDs) have improved the prognosis of autoimmune inflammatory arthritides but a large fraction of patients display partial or nonresponsiveness to front-line DMARDs. Here, an immunoregulatory approach based on sustained joint-localized release of all-trans retinoic acid (ATRA), which modulates local immune activation and enhances disease-protective T cells and leads to systemic disease control is reported. ATRA imprints a unique chromatin landscape in T cells, which is associated with an enhancement in the differentiation of naïve T cells into anti-inflammatory regulatory T cells (Treg) and suppression of Treg destabilization. Sustained release poly-(lactic-co-glycolic) acid (PLGA)-based biodegradable microparticles encapsulating ATRA (PLGA-ATRA MP) are retained in arthritic mouse joints after intra-articular (IA) injection. IA PLGA-ATRA MP enhance migratory Treg which in turn reduce inflammation and modify disease in injected and uninjected joints, a phenotype that is also reproduced by IA injection of Treg. PLGA-ATRA MP reduce proteoglycan loss and bone erosions in the SKG and collagen-induced arthritis mouse models of autoimmune arthritis. Strikingly, systemic disease modulation by PLGA-ATRA MP is not associated with generalized immune suppression. PLGA-ATRA MP have the potential to be developed as a disease modifying agent for autoimmune arthritis.”

Video: https://youtu.be/XRirpeY8hPA